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Accepted 4 January 2015Myoclonic epilepsies are frequently related to mitochondrial
disorders, lysosomal disorders and proteinopathic neurodegener-
ative diseases. Familial cortical myoclonic tremor with epilepsy
(FCMTE) is a genetic form of myoclonic epilepsy. FCMTE is deﬁned
by an autosomal dominant inheritance, adult onset cortical
myoclonic tremor and inconstant seizures. Electrophysiologic
examinations show cortical hyperexcitability (paroxysmal poly-
spike and wave activity on EEG with a marked photosensitivity,
recording of enlarged cortical components of somatosensory
evoked potential, enhanced long-loop reﬂex (C-reﬂex), and cortical
transients preceding the myoclonic jerks using the jerk-locked
back-averaging technique). Type 3 FCMTE (FAME3/FCMTE3) is
linked to the locus 5p15.31-p15.1 [1]. No obvious candidate gene
(like ion channel subunit gene for example) is localized to this
locus. Actually, no mutation has been found and the biological
mechanism involved in FCMTE3 remains unclear. Fronto-striatal
dysfunction, gait impairment and cognitive disorders appearing
after several decades of disease progression were reported in
FCMTE3 [2].
The patient was a right-handed 52-year-old man with high
level of education. No previous personal medical history or
neurodevelopmental disorder was reported. A generalized seizure
was reported to have occurred at the age of 25, and with a mild
bilateral myoclonus in upper limbs beginning at the age of* Correspondence to: Department of Neurology, Besanc¸on University Hospital,
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without aura and visual intolerance to light and contrast without
EEG abnormalities were also reported at the age of 25. Triggering
factors were physical exercise, vibration and stress. The patient
had been stable for 20 years under valproate (VPA) treatment
(1000 mg/day). Genetic linkage to 5p15.31-p15 (FCMTE3) was
found. The patient (IV-6) and his pedigree have previously been
described in detail [1]. He was therefore considered as a
‘‘paucisymptomatic’’ type 3 familial cortical myoclonic tremor
with epilepsy (FCMTE3). Written informed consent was obtained
from the patient. The study received approval from the ethical
standards committee on human experimentation.
At the age of 50, the patient complained of language disorders.
Since the disease onset, the myoclonus was stable and mild and the
epilepsy was well controlled, with only 3 episodes in 25 years.
Neuropsychological evaluation showed cognitive disorders with a
logopenic syndrome (anomia, lexical access disorders, reduced
spontaneous ﬂuency, and length-dependent deﬁcit) and a verbal
short term memory impairment (Table 1). No Parkinsonism, gait
disorder or visuospatial disorders was observed. No other neurolog-
ical abnormalities were observed. No loss of autonomy was reported.
VPA level was within therapeutic values (62 mg/mL, accepted
range 50–100). Amoniemia level was normal. No disorders related
to mitochondriopathy or lysosomial disorders (like diabetes,
hearing loss, neuropathy, leukoencephalopathy, myocardiopathy,
retinopathy, myopathy, nephropathy, hepatopathy, lactic acidosis)
were found.
Neuroimaging examinations showed diffuse cortical and basal
abnormalities (Fig. 1). MRI showed diffuse bilateral frontoparietal,
mesencephalic, cerebellar and left hippocampic atrophy without
white matter hyperintensity. Brain perfusion SPECT (99mTc-
HMPAO) showed predominantly left-sided bilateral fronto-par-
ieto-occipital hypoperfusion. DAT-SPECT showed loss of dopamine
transporter (DAT) in the left striatum (mean striatal–occipital ratio
was 0.91 on left side vs 1.32 on the right side, N > 1.2).
Electroencephalogram follow-up showed no abnormality.
A progressive switch from VPA to levetiracetam was proposed.
However, he declined because the decrease in VPA had led to a
severe increase in his father’s myoclonus (III-10) [2].
Our case underpins the frontostriatal abnormalities that have
been reported in severe form of FCMTE3 during aging. Those
abnormalities could explain cognitive and visual symptoms. Inserved.
Table 1
Neuropsychological and logopedic examinations.
Mini Mental Satus Examination (/30) 30
Mattis Dementia Rating Scale (/144) 144
Forward digit span (items) 4a
Backward digit span (items) 4a
Trail making test part A (s) 28
Trail making test part B (s) 115a
Verbal comprehension test (/24) 24
Picture Naming Test 80 items (/80) 75a
Naming to verbal description and deﬁnition task
Abstract words (/15) 13a
Concrete words (/15) 12a
Word deﬁnition (/28) 16a
Verbal ﬂuency
Semantic ﬂuency (words) 39
Phonological ﬂuency (words) 21
Word repetition (/39) 39
Sentence repetition (/3) 3
a Pathological result.
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posterior cortical dysfunction was also observed and can explain
the logopenic syndrome [3]. Occipitoparietal and basal abnormali-
ties can participate in the visual intolerance to the light and
contrast as well [2].
These abnormalities were initially considered to be conse-
quences of chronic myoclonus. However, a primitive etiological
mechanism of FCMTE is not excluded [2]. In our patient and the
two cases previously described, the predominantly left-sided
dysfunction suggests a lateralized tropism of FCMTE3. As theFig. 1. Neuroimaging results: MRI (A and B: axial T1 sequence; C: coronal hippocampic T
bilateral hippocampal atrophy, predominating on the left side (C). Brain perfusion S
predominantly left-sided bilateral frontoparietooccipital hypoperfusion and no basal abn
(DAT) in the left striatum.myoclonus was not predominant in the right side, these results
support a primitive neurodegenerative dysfunction in FCMTE3. In
the previous study, both FCMTE3 patients presented severe
myoclonus and were over 65 when gait disorders and major
cognitive decline occurred [2]. Our observation shows that
corticobasal abnormalities can occur in a younger FCMTE3 patient
(52 year old) with very mild myoclonus and infrequent seizures.
Those results suggest that corticobasal abnormalities are indepen-
dent of severity of myoclonus and epilepsy. Moreover, none of the
sixteen FMCTE3 patients present cognitive neurodevelopmental
disorder [2] and our had a high level of education and no
neurodevelopmental linguistic disorders. Therefore, age might
have play a role in the occurrence of cognitive disorders and
corticobasal dysfunctions. Our results suggest that those symp-
toms can possibly begin around ﬁfty year old by a mild cognitive
impairment and sometimes can evolve into a major cognitive
impairment with severe myoclonus and gait disorders around
sixty year old.
From a pathogenic point of view, a mutation of aminocarbox-
ymuconate semialdehyde decarboxylase gene (ACMSD), an enzyme
that might be involved in dopaminergic metabolism, was found in
another type 2 FCMTE family: it supports a possible primitive
dopaminergic dysfunction in this syndrome [4], as does the DAT-
scan results of our patients.
Here, another possible explanation is an iatrogenic origin
induced by chronic VPA treatment. VPA may induce Parkinsonism
and cognitive impairment. However, encephalopathy due to VPA
would have result in confusion with a diffuse, ﬂuctuating cognitive
impairment, diminished level of consciousness, EEG abnormalities,
and hyperammonemia. Besides, the patient had taken VPA2 sequence) showing bilateral frontopariteal (A), mesencephalic, cerebellar (B) and
PECT (Tc99m-HMPAO) (D, E) showing bilateral hippocampal hypoperfusion (D),
ormalities (E). DAT-SPECT (I-123-FP-CIT) (F) showing loss of dopamine transporter
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inﬂuence of chronic VPA treatment on DAT-SPECT, and the effect of
chronic VPA treatment in the dopaminergic system remains
unclear: toxicity on dopaminergic neurons, a neuroprotective
effect or an increase in dopamine transporter gene expression
[2]. However, an iatrogenic origin would have result in a
symmetric cerebral toxicity.
In conclusion, FCMTE3 might have a neurodegenerative
evolution during aging independent of the severity of epilepsy
and myoclonus. Clinical and imaging ﬁndings raise hypotheses
about the physiopathology of this evolution. Both dopaminergic
and cortical dysfunctions may explain the phenotypic character-
istics of this patient. Further functional, neuropathological, and
genetic analyses with a systematic follow-up are needed to
better understand the physiopathology and the timing of these
dysfunctions.Conﬂict of interest
None declared.
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